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Abstract  68 
 69 
Non-alcoholic fatty liver (steatosis) and steatohepatitis (NASH) are hepatic complications of 70 
metabolic syndrome. Endoplasmic reticulum (ER) stress is proposed as a crucial disease mechanism 71 
in obese and insulin resistant animals (such as ob/ob mice) with simple steatosis but its role in NASH 72 
remains controversial. We therefore evaluated the role of ER stress as a disease mechanism in 73 
foz/foz mice, which develop both the metabolic and the histological features that mimic human 74 
NASH. 75 
We explored ER stress markers in the liver of foz/foz mice in response to high-fat diet (HFD) after 76 
several time points. We then evaluated the effect of treatment with ER stress inducer tunicamycin, 77 
or conversely with ER protectant tauro-ursodeoxycholic acid (TUDCA) on the metabolic and hepatic 78 
features.  79 
Foz/foz mice are obese, glucose intolerant and develop NASH characterized by steatosis, 80 
inflammation, ballooned hepatocytes and apoptosis from 6 weeks of HFD feeding. This was not 81 
associated with activation of the upstream unfolded protein response (phospho-eIF2α, IRE1α 82 
activity, spliced Xbp1). Activation of JNK and up-regulation of Atf4 and Chop transcripts were 83 
however compatible with a “pathologic” response to ER stress. We tested it by intervention 84 
experiments. Induction of chronic ER stress failed to worsen obesity, glucose intolerance and NASH 85 
pathology in HFD-fed foz/foz mice. In addition, ER protectant TUDCA, although reducing steatosis, 86 
failed to improve glucose intolerance, hepatic inflammation and apoptosis in HFD-fed foz/foz mice. 87 
These results show that signals driving hepatic inflammation, apoptosis and insulin resistance are 88 
independent of ER stress in obese, diabetic mice with steatohepatitis. 89 
  90 
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Introduction 91 
 92 
Easy access to food in our modern societies has led to decreased physical activity and over-eating 93 
which dramatically increase the risks of obesity-related type 2 diabetes, cardiovascular and non-94 
alcoholic fatty liver diseases (NAFLD). These conditions each have insulin resistance as a common 95 
denominator. In this metabolic context, several factors, among which hyperglycaemia, 96 
hyperinsulinemia, adipose inflammation and deregulated adipokine production pattern, digestive 97 
and gut-derived factors act to perturb liver lipid homeostasis leading to liver lipid accumulation 98 
[16;33]. In some patients, in addition to steatosis, hepatocellular injury and chronic inflammation 99 
develop, resulting in a progressive fibrotic disease termed non-alcoholic steatohepatitis (NASH).  100 
 101 
The high protein synthesis capacity of hepatocytes requires a well-developed endoplasmic reticulum 102 
(ER). Various stress conditions, amongst which nutrient overload, oxidative stress, hypoxia or amino 103 
acid and glucose deprivation affect ER homeostasis and protein folding capacity. ER stress triggers 104 
the unfolded protein response (UPR) elements of which converge to increase folding capacity 105 
through chaperone production and reduction of protein loading through enhancing ER-associated 106 
protein degradation (ERAD) and attenuation of translation [27], thereby decreasing ER contrains. At a 107 
homeostatic state, the chaperone glucose-regulated protein 78 (Grp78/BiP) binds and blocks the 108 
activation of 3 ER trans-membrane proteins, i.e. inositol-requiring-1α (IRE1α), protein kinase double-109 
stranded RNA-dependent-like ER kinase (PERK) and activating transcription factor-6 (Atf6) [9]. When 110 
misfolded or unfolded proteins accumulate in the ER, Grp78 releases those 3 sensors, leading to their 111 
activation. IRE1α, an endoribonuclease, splices X-box binding protein 1 (Xbp1) which stimulates the 112 
expression of Grp78 and ERAD enhancing mannosidase-like protein (Edem). PERK, via 113 
phosphorylation of eukaryotic translation initiation factor-2α subunit (eIF2α), globally inhibits protein 114 
translation. Active Atf6 translocates to the nucleus and enhances the transcription of genes encoding 115 
protein chaperones Grp78 and heat shock protein 90 (Hsp90/Grp94).  116 
 117 
In addition to its primarily cytoprotective response, UPR has collateral side effects by inducing 118 
apoptosis, inflammation, insulin resistance and fat accumulation. Because of these deleterious 119 
consequences, it has been suggested that ER stress may participate to the development and 120 
propagation of NASH [3]. The ER stress pathologic response includes: enhanced expression and 121 
nuclear translocation of pro-apoptotic C/EBP homologous protein (Chop), induced mainly by PERK-122 
dependent up-regulation of Atf4 transcription factor [29] but also by Atf6 and IRE1α pathways; PERK- 123 
and IRE1α-mediated induction of pro-inflammatory nuclear factor-κB; IRE1α-dependent activation of 124 
the c-Jun N-terminal kinase (JNK) which in turn impairs insulin signalling and can lead to apoptosis; 125 
PERK and Grp78-mediated activation of sterol regulatory element binding protein-1c (Srebp1c), the 126 
master regulator of de novo lipogenic program. In this way, the pathways activated during the 127 
response to ER stress could integrate lipid dysbiosynthesis, insulin resistance, inflammation and cell 128 
death in relation to excess cellular nutrient. It is therefore logical that ER stress has been envisaged 129 
as a pivotal pathogenic mechanism in NASH [3].  130 
 131 
On the other hand, the evidence that ER stress mediates as opposed to accompanies development of 132 
fatty liver disease and transition to NASH is fragmentary. In the liver of leptin-deficient ob/ob mice, 133 
ER stress is evident and has been related to lipogenesis and hepatic insulin resistance [12;23]. 134 
However, ER stress does not necessarily accompany fatty liver disease in different genetic or diet-135 
induced rodent models [38]. In humans, Puri et al. showed that, among the UPR markers, only 136 
phospho-eIF2α was increased in both NAFLD and NASH patients while the spliced form of XBP1 137 
protein, found in controls and NAFLD, was low in NASH patients [25]. Gregor et al. showed that 138 
gastric bypass reduced phospho-eIF2α and Grp78 levels in liver and adipose tissue from obese 139 
patients, but data in liver were derived from only 4 liver biopsies [8]. Finally, Kumashiro et al. showed 140 
that in liver biopsies from 37 obese patients, ER stress markers correlated poorly with NAFLD-141 
associated hepatic insulin resistance [13]. In summary, although several studies point to the UPR and 142 
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initiation of some ER stress signalling pathways in human and experimental NAFLD, mechanistic 143 
evidence that ER stress activates key pathogenic pathways in NASH is lacking.  144 
 145 
We have used a metabolic syndrome model for NASH to clarify the operation and mechanistic 146 
significance of ER stress. Postnatally, Alms1 mutant (foz/foz) mice lose hypothalamic neuronal cilia, 147 
location of key appetite sensing receptors, causing hyperphagic obesity with hyperleptinemia, 148 
hypoadiponectinemia and steatosis [11]. When fed a high fat diet, foz/foz mice rapidly develop 149 
obesity-related metabolic syndrome [2] and liver injury that recapitulates all the features of NASH: 150 
steatosis, liver inflammation, hepatocellular injury including ballooning and apoptotic cell death as 151 
well as progressive fibrosis [1]. We first measured expression of UPR and ER stress response proteins 152 
at various time points upon HFD feeding. In order to interrogate a causal relationship between ER 153 
stress response and liver pathology, we then performed interventions designed firstly to induce ER 154 
stress by a known mechanism (tunicamycin), and secondly to abrogate ER stress with the ER 155 
chaperone, tauro-ursodeoxycholic acid (TUDCA). Our data seriously challenge the notion that ER 156 
stress promotes the development of either the metabolic phenotype or steatohepatitis pathology in 157 
mice whose adipokine responses to obesity are the same as humans. 158 
 159 
 160 
Material and methods  161 
 162 
Animals and diets 163 
Male foz/foz (Alms1 mutant) NOD.B10 mice were bred and maintained in a 12-h light/dark cycle in 164 
the animal facility of Université catholique de Louvain (Brussels, Belgium). After weaning, mice were 165 
fed a standard rodent chow diet (ND) containing 2.83 kcal/g (16% fat, 54% carbohydrate, 30% 166 
protein, 0.001% cholesterol [wt/wt]; A03 from SAFE-diets, France) or a high-fat diet (HFD) which 167 
contains 5.24 kcal/g (60% fat, 20% carbohydrate, 20% protein, 0.03% cholesterol; D12492 from 168 
Research Diets, USA). Female WT and foz/foz mice were bred in the animal facility of ANU Medical 169 
School at The Canberra Hospital (Garran, ACT, Australia). All experiments were performed with 170 
approval of the local University Animal Welfare Committee. 171 
 172 
Treatments 173 
Male foz/foz mice were fed the ND or HFD for 3 days (5 mice per group), 6 weeks (≥ 5 mice per 174 
group) or 16 weeks (3 mice per group). Female WT and foz/foz mice were fed chow or HFD for 12 or 175 
24 weeks (n=6 per group). 176 
Tunicamycin (T7765 from Sigma) was dissolved at 200 μg/mL in 4.0% DMSO/10 mM Tris pH 8.0 [28]. 177 
Ten week-old male foz/foz mice under ND received an intraperitoneal (IP) injection of 1.0 mg/kg BW 178 
or an equivalent volume of diluent (6 mice per group) and were sacrificed 6 hours after treatment for 179 
the acute tunicamycin treatment. For chronic ER stress activation, another group of foz/foz mice 180 
were fed HFD for 5 weeks. After one week HFD feeding, an Alzet minipump (model 1004) loaded with 181 
tunicamycin or diluent was implanted in the inter scapulae subcutaneous tissue (5 per group) such as 182 
to obtain a continuous release of the product (10 ng/kg BW/day [17]) during 4 weeks. Mice were 183 
kept under HFD for the duration of treatment. 184 
To inhibit ER stress, chemical chaperones were administered in a therapeutic setting. After 4 weeks 185 
HFD feeding in male foz/foz mice, treatment was initiated and repeated twice daily for 14 days. HFD 186 
was maintained during treatment. Ob/ob mice (7 week-old; Janvier, France) were used as a positive 187 
control and treated in parallel (same dose and simultaneously) with foz/foz mice. As chemical 188 
chaperones, we used 4-phenyl butyrate (PBA) in one hand and tauro-ursodeoxycholic acid (TUDCA) 189 
on the other. PBA was administered to mice (4 per group) by IP injection (water as vehicle) at the 190 
doses of 250 or 500 mg/kg twice a day (9 am and 6 pm, 0.5 or 1 g/kg BW/d). 191 
Tauro-ursodeoxycholic acid (TUDCA) was administered to mice by IP injection (water as vehicle) at a 192 
dose of 250 mg/kg twice a day (9 am and 6 pm, 500 mg /kg BW/d). TUDCA treatment decreased food 193 
intake both in ob/ob and HFD-fed foz/foz mice (-7.6 kcal/day for both strains, p<0.001, n=3-4 per 194 
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group). Therefore, to clearly dissociate the effects of TUDCA from those due to decreased energy 195 
intake, mice were paired according to their body weight and glycaemia, and each control was pair-196 
fed the same amount of food as that eaten by the corresponding TUDCA-treated mouse the day 197 
before (6-7 per group). 198 
Please see supplementary experimental procedures. 199 
 200 
Data analyses 201 
Data are presented as means ± standard deviation (SD). Quantitative variables deviating from normal 202 
distribution were log-transformed. Differences between groups were analysed using the Student’s t-203 
test. Paired tests were performed between TUDCA-treated mice and their respective pair-fed 204 
controls. P values <0.05 were considered as statistically significant.  205 
 206 
Results 207 
 208 
High-fat diet-fed foz/foz mice develop metabolic and hepatic phenotypes similar to those 209 
encountered in human NASH 210 
As previously reported, 6 weeks HFD induces obesity, adiposity and hepatomegaly in male foz/foz 211 
mice (Table 1). This was associated with fasting hyperglycaemia and pronounced glucose intolerance 212 
(Table 1, Figure 1 A). At this stage, liver histology showed macrovesicular steatosis with fat droplets 213 
present in more than 70% of hepatocytes (grade 3) (Figure 1 B). Biochemical analyses confirmed a 214 
6-fold increase in hepatic lipids in HFD- versus ND-fed foz/foz mice (Table 1). Inflammatory foci were 215 
scattered through the parenchyma and hepatic F4/80 and CD68 transcript levels were significantly 216 
increased signifying macrophage activation (Figure 1 B & C). Ballooned hepatocytes were readily 217 
observed, as was hepatocellular apoptosis, indicated by the presence of apoptotic bodies and of 218 
M30-immunopositive hepatocytes (Figure 1 D). Elevated serum ALT level confirmed liver injury (Table 219 
1). Thus, livers of HFD-fed foz/foz mice conform to all the criteria for a diagnosis of NASH. As 220 
reported elsewhere, upon continuation of HFD for longer period, severe fibrosing NASH will develop 221 
[1;15].  222 
 223 
High-fat diet does not induce obvious ER stress in foz/foz mice 224 
Compared to their ND-fed controls, we found no molecular signature of UPR in 6 week HFD-fed 225 
foz/foz livers: there was no increased phosphorylation of eIF2α or IRE1α upregulation, no splicing of 226 
Xbp1 and no increased expression of chaperones Grp78 and Hsp90 or upregulation of Edem (Figure 2 227 
A-C). Also the expression of genes involved in de novo lipogenesis and phospholipid synthesis (Pemt) 228 
were not induced or rather reduced (Fasn, Scd-1) (Figure 2 D). This particularly contrasted with the 229 
ob/ob model which presented activation of the UPR and enhanced lipogenic genes expression, as 230 
already reported by others [12;23] (Supplementary Figure 1).  231 
When activation of the UPR fails to restore homeostasis, the pro-apoptotic and pro-inflammatory 232 
pathways mentioned in the introduction prevail. As previously reported [14;35], JNK phosphorylation 233 
increased in HFD-fed foz/foz mouse livers compared to ND-fed counterparts (Figure 2 E). Further, 234 
Atf4 and Chop mRNA expression were significantly increased (Figure 2 F). However, nuclear Chop 235 
protein was not detectable (Figure 2 G) and only pro-apoptotic Bim was up-regulated but no other 236 
Chop targets such as Gadd34 or Trib3. This highly suggests that Chop does not mediate apoptosis in 237 
this model. 238 
UPR activation was also investigated at different time points of HFD feeding. A short term HFD 239 
feeding (3 days) did not induce UPR in male foz/foz mice (Supplementary Figure 2 A-C). Also, UPR 240 
was not evidenced in foz/foz mice fed HFD for 16 weeks, which present a more advanced stage of 241 
steatohepatitis (Supplementary Figure 2 A-B-D). Finally, in female foz/foz mice which also develop 242 
NASH [15], there was also no up-regulation of Grp78 or nuclear Chop expression after 12 or 24 weeks 243 
of HFD feeding (Supplementary Figure 2 E-G). 244 
 245 
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Treatment with ER stress inducer does not aggravate metabolic and hepatic phenotype of HFD-246 
fed foz/foz mice 247 
Because of the theoretical concern that unidentified functions of Alms1 in the liver could alter a 248 
biological response such as ER stress, we sought to confirm that a known inducer of ER stress 249 
operated as anticipated in this line. Tunicamycin inhibits protein glycosylation leading to the 250 
accumulation of unfolded proteins in the ER lumen. As shown in Supplementary Figure 3, acute 251 
tunicamycin co-ordinately induced PERK-dependant eIF2α phosphorylation and Atf4/Chop 252 
expression and nuclear translocation, IRE1α expression and splicing of Xbp1, expression of 253 
chaperones and protein degradation machinery. However tunicamycin did not induce JNK 254 
phosphorylation in livers of foz/foz mice.  255 
We then assessed whether prolonged ER stress activation would enhance metabolic disturbances 256 
and promote NASH in HFD-fed foz/foz mice. We therefore implanted tunicamycin-filled minipumps 257 
into HFD-fed foz/foz mice. Compared to vehicule-treated HFD-fed foz/foz controls, 4 weeks of 258 
tunicamycin infusion induced a UPR assessed by a significant increase in hepatic Grp78 and Hsp90 259 
expression and in JNK phosphorylation (Figure 3 A-C). This was associated with decreased AKT 260 
phosphorylation on the threonine residue (Supplementary Figure 4 B). Despite this negative effect on 261 
insulin signalling pathway, chronic tunicamycin infusion did not further increase plasma glucose and 262 
c-peptide levels or glucose intolerance (Table 2 & Figure 3 E) in HFD-fed foz/foz mice. Similarly, it did 263 
not aggravate liver pathology. Thus, serum ALT levels and hepatic lipid content were similar in 264 
tunicamycin-treated and control HFD-fed foz/foz mice (Table 2). On histological examination (Figure 265 
3 F and H), the degree of steatosis (52 ± 22% versus 32 ± 16% of fatty hepatocytes), the number of 266 
ballooned hepatocytes (1.8 ± 1.5 versus 1.3 ± 1.1 per high power field (20X), p=0.57) and the number 267 
of M30 positive hepatocytes (4.49 versus 2.73 per high power field, p=0.07) were not significantly 268 
different in tunicamycin- and PBS-treated HFD-fed foz/foz mice. Tunicamycin may have reduced the 269 
extent of inflammation, as reflected by the lower number of inflammatory foci compared to PBS-270 
treated HFD-fed foz/foz mice (0.9 ± 0.6 versus 2 ± 0.7 per field (10X), p=0.003) with no significant 271 
change in F4/80 and CD68 mRNA expression (Figure 3 G).  272 
 273 
The ER stress chaperone, tauro-ursodeoxycholic acid does not improve glucose tolerance or liver 274 
injury in HFD-fed foz/foz mice.  275 
If ER stress always plays a role in the metabolic abnormalities of unhealthy obesity or in the 276 
pathogenesis of steatohepatitis, administration of agents that are known to abrogate an ER stress 277 
response should, at least partly, mitigate against these effects. Others have shown that the chemical 278 
chaperones 4-phenyl butyrate (PBA) and tauro-ursodeoxycholic acid (TUDCA) counteract ER stress 279 
and improve glucose homeostasis and steatosis in ob/ob mice [24]. We therefore examined the 280 
effects of these ER protectants in HFD-fed foz/foz mice and we used ob/ob mice as a positive control 281 
to validate the treatments. Foz/foz mice received PBA or TUDCA treatment during the last 2 weeks of 282 
a 6-week HFD feeding protocol. The chemical chaperone PBA which protected ob/ob mice against ER 283 
stress (data not shown) was highly toxic to foz/foz mice so that the mortality, which exceeded 70%, 284 
precluded interpretation. We then used TUDCA and observed that it reduced food intake (-7.6 285 
kcal/day for both strains, p<0.001).  Thus, we used pair-fed mice as controls to strictly dissociate any 286 
pharmacological effects of TUDCA from those attributable to decreased nutrient load. As expected, 287 
TUDCA treatment to ob/ob mice significantly improved steatosis and glucose homeostasis, and 288 
decreased the expression of UPR markers (Supplementary Figure 5). In HFD-fed foz/foz mice, the 289 
effect of TUDCA on ER homeostasis was confirmed by the decrease in eIF2α phosphorylation and 290 
IRE1α protein levels (Figure 4 A). This was associated with a further decrease in the expression of 291 
lipogenic genes (Figure 4 C) as well as Nqo1, a marker of oxidative stress (2-fold decrease, p=0.04). 292 
However, TUDCA treatment had no significant effect on JNK phosphorylation or on the expression of 293 
Chop and the target genes that were enhanced in HFD foz/foz livers (Figure 4 A & B).  294 
At the physiological level, TUDCA treatment failed to decrease hyperglycaemia, serum c-peptide 295 
levels or to improve glucose tolerance and hepatic insulin signalling in HFD-fed foz/foz mice (Table 3, 296 
Figure 4 D and Supplementary Figure 3). TUDCA did reduce the severity of hepatic steatosis 297 
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histologically, and this effect was confirmed by a significant reduction in total hepatic lipid content 298 
(Table 3). However, TUDCA failed to reduce the number of inflammatory foci or the activation of 299 
Kupffer cells in the liver of HFD-fed foz/foz mice (Figure 4 E-F). Besides, ballooned hepatocytes were 300 
still readily observed in TUDCA-treated foz/foz livers and there was no improvement in M30 301 
cytokeratin fragmentation immunostaining (Figure 4 G). We interpret these results as indicating that 302 
ER protectant, despite decreasing steatosis, does not improve glucose homeostasis, unlike in ob/ob 303 
mice, or the kind of liver injury that comprises transition to steatohepatitis in HFD-fed foz/foz mice. 304 
 305 
 306 
 307 
 308 
 309 
Discussion 310 
 311 
Perturbation in the normal function of the endoplasmic reticulum triggers a signalling network that 312 
coordinates adaptive, inflammatory and apoptotic responses. There is accumulating evidence 313 
implicating prolonged ER stress in the development and progression of many diseases, in particular in 314 
obesity-associated insulin resistance and NAFLD. A link between activation of the UPR and hepatic 315 
insulin resistance and steatosis has been demonstrated in ob/ob mice [12;23;24]. Increased eIF2α 316 
expression has been reported in human NASH livers [25], but with no evidence of aggravation in 317 
NASH livers compared to those with simple steatosis. Mice mutated for the ER secretory pathway 318 
protein, Sec61alpha1, develop hepatic steatosis, progressive liver injury with fibrosis when 319 
challenged with a HFD but intervention studies alleviating ER stress to test for causality were not 320 
reported [18].  321 
 322 
To interrogate the participation of ER stress and UPR to obesity-associated liver injury, we used HFD-323 
fed foz/foz mice which exhibit, in addition to steatosis, hepatic inflammation and hepatocellular 324 
injury that evolve with time into fully established NASH with typical perisinusoidal fibrosis [1;15]. If 325 
indeed a pathologic ER stress response develops, we reasoned that chemical induction of ER stress 326 
would worsen insulin resistance and apoptotic cell death. Conversely, ER protectants would have an 327 
opposite protective effect. Strikingly, tunicamycin-induced ER stress failed to significantly aggravate 328 
the metabolic and hepatic phenotype of HFD-fed foz/foz mice. Moreover, TUDCA, an ER protectant, 329 
despite decreasing steatosis, did not improve glucose homeostasis or liver injury in HFD-fed foz/foz 330 
mice. None of these findings provide support for the operation of ER stress in the pathophysiology 331 
and cellular pathology of insulin resistance-related steatohepatitis. 332 
 333 
Among ER stress response markers, we found no signature of an adaptive response converging to 334 
reduce ER protein overload. Increased Atf4 and Chop transcripts and activation of JNK seen in HFD-335 
fed foz/foz livers may be interpreted as part of an ER stress response. However, the causal 336 
relationship between those signalling events and UPR is not established in the absence of upstream 337 
activation of ER-transmembrane proteins. Further, disturbed ER homeostasis and UPR are not a 338 
unique mechanism converging to activate these factors. LPS, NO or oxidative stress [21;22] as well as 339 
DNA damage (chop is also known as Gadd153 -growth arrest and DNA damage inducible gene [6;30]) 340 
are potent stimuli for Chop up-regulation. Further analyses are needed to unravel the signals that up-341 
regulate Chop expression in foz/foz mice. Importantly, increased Chop transcript, as it is not 342 
associated with increased nuclear translocation of the protein, is most likely irrelevant for inducing 343 
apoptosis in HFD-fed foz/foz livers. 344 
 345 
The currently accepted model for JNK activation by free fatty acids involves ER stress through IRE1α 346 
[34]. Contradicting this paradigm, Sharma et al. showed that fatty acid-induced JNK activation was 347 
not inhibited in the absence of IRE1α and that fatty acid-induced cell death in hepatocytes was 348 
independent of IRE1α [31]. Therefore, the fact that JNK activation was observed in HFD-fed foz/foz 349 
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mice in the absence of IRE1α activation can readily be explained by the direct effects of lipotoxicity 350 
from accumulated free fatty acids [20] as well as free cholesterol (Gan and Van Rooyen 2013; 351 
unpublished data) rather than as part of a pathologic response to ER stress.  352 
 353 
Despite the evident absence of ER stress in HFD-fed foz/foz mice, TUDCA treatment did reduce 354 
steatosis severity. In another genetic model of obesity, Yang et al. suggested that TUDCA improved 355 
hepatic steatosis by reducing oxidative stress [38]. Nqo1, a marker of oxidative stress, and several 356 
key lipogenic genes were decreased in TUDCA-treated foz/foz mice, supporting a role of oxidative 357 
stress in anti-steatotic effect of TUDCA. Furthermore, TUDCA, which is a hydrophilic bile acid,  358 
stimulates the synthesis and biliary secretion of phosphatidyl choline [19]. An increased fraction of 359 
hepatic free fatty acid may thus exit the liver as phospholipids and not participate to triglyceride 360 
synthesis, contributing to reduced steatosis. 361 
 362 
As our results in foz/foz mice differ from those previously reported by elegant experimentation in 363 
other models, we consider that at least some of the earlier findings could be model-specific, many 364 
being in animals lacking leptin (ob/ob mice) [24] or a functional leptin receptor (db/db mice) [26]. To 365 
establish this we performed similar studies in ob/ob mice and were able to confirm the previously 366 
reported, adaptive response to ER stress in ob/ob livers and a beneficial effect of ER-protectants on 367 
steatosis and glucose homeostasis. Xu et al also reported differential effects of an ER protectant on 368 
glucose homeostasis in different models of type 2 diabetes: while PBA normalized hyperglycaemia in 369 
ob⁄ob mice, it had no glucose-lowering effect in Goto-Kakizaki rats and had no preventive or 370 
therapeutic effects on insulin resistance and hyperglycaemia in mice treated with hydrocortisone 371 
[37]. Therefore, the operation of ER stress could be related to the mechanisms causing metabolic 372 
alterations. Fu et al. demonstrated in ob/ob mice that lipogenesis, by altering the composition of ER 373 
membranes, causes the dysfunction of ER-anchored proteins and in particular that of the calcium 374 
pump SERCA resulting in modification of calcium fluxes impacting on protein folding capacity [7]. De 375 
novo lipogenesis is a prominent mechanism for steatosis in leptin-deficient mice [4;32]. This is not 376 
the case in obese humans with NAFLD [5], in which less than 30% of total hepatic lipid arises from 377 
hepatic lipogenesis, nor is it the case in foz/foz livers, in which steatosis results from increased 378 
delivery of fatty acid to the liver and altered lipid partitioning [14;15]; the latter finding is very similar 379 
to that observed by lipid turnover studies in humans [5]. 380 
 381 
In our study, TUDCA treatment did not have benefice on NASH progression. A similar observation 382 
was also reported by Henkel et al. applying TUDCA treatment in mice with MCD-induced 383 
steatohepatitis [10]. Noteworthy, the unconjugated form of this bile acid (UDCA) investigated for 384 
many years in the treatment for NASH is ineffective and cannot be recommended for NASH 385 
treatment [36]. Other non-UDCA bile acids, regulating metabolism by binding to the nuclear 386 
hormone receptor farnesoid X receptor and to a transmembrane bile acid receptor, TGR5, may 387 
deserve more attention. 388 
 389 
In conclusion, this study shows that ER stress is not a feature associated with insulin resistance and 390 
steatohepatitis in the foz/foz model and that altering or protecting ER functions has no effect on 391 
insulin resistance and liver disease propagation. Data from earlier models may be model-specific. 392 
Since the progressive liver disease of the HFD-fed foz/foz mice, including hepatocellular injury with 393 
ballooning, apoptosis, inflammation and later accompanied with pericellular fibrosis, is more relevant 394 
to human NAFLD and NASH than is leptin-deficiency in ob/ob mice, convincing evidence gained from 395 
clinical studies would be required to provide support to the therapeutic effect of ER stress modifiers 396 
in human NASH.  397 
 398 
 399 
Clinical Perspectives 400 
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Earlier studies have shown that counteracting ER stress using chemical chaperones such as TUDCA 401 
had a therapeutic benefit in obese and insulin resistant mouse models that develop simple steatosis. 402 
Using a unique model that develops the progressive liver disease in the metabolic context as seen in 403 
human NASH, we show that ER stress does not contribute to the pathogenesis of NASH and that 404 
TUDCA fails to alleviate glucose intolerance and hepatic inflammation and apoptosis, thus limiting 405 
the therapeutic potential of chemical chaperones to treat NASH. 406 
 407 
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Figure legends  536 
 537 
Figure 1: High-fat diet-fed foz/foz mice present all the metabolic and histologic features of 538 
human NASH  539 
(A) Curves of glycaemia during intra-peritoneal glucose tolerance test and area under the glucose 540 
curves (AUC) in foz/foz mice fed normal diet (ND-plain forms) or high-fat diet (HFD-open forms) 541 
during 6 weeks. (B) Haematoxylin and eosin staining of liver sections showing steatosis in HFD-fed 542 
foz/foz mice compared to ND (original magnification X10). Higher magnification figures (X20) 543 
highlight ballooned hepatocytes (arrows, a), mitosis (b), nuclear glycogen inclusion (c), apoptotic 544 
body (d) and inflammatory infiltrates (e) in HFD foz/foz livers. (C) F4/80 and CD68 mRNA levels 545 
assessed by reverse transcription and real time PCR on whole liver RNA. (D) Immunohistochemistry 546 
using antibody against cleaved cytokeratin 18 (M30) demonstrating apoptotic hepatocytes in HFD 547 
foz/foz livers (original magnification X20). *p<0.05 548 
 549 
Figure 2: Adaptive and pathologic ER stress responses in foz/foz mice 550 
RNA and total proteins were extracted from livers of normal diet (ND or plain bars) or high-fat diet-551 
fed foz/foz mice (HFD or open bars) to evaluate (A) eIF2α phosphorylation (parts of the same 552 
immunoblot) and IRE1α protein levels by western blot (left panel) and quantification (right panel); (B) 553 
Xbp1 splicing by reverse transcription PCR (products loaded on agarose gel; spliced=147 bp, 554 
unspliced=173 bp; T, positive control with tunicamycin); (C) expression of target genes of adaptive 555 
UPR by RT-qPCR; (D) expression of lipogenic genes measured by RT-qPCR; (E) phosphorylation of JNK 556 
by western blot (parts of the same immunoblot) and quantification; (F) expression of target genes of 557 
pathologic ER stress response by RT-qPCR; (G) nuclear Chop protein level assessed by western blot. 558 
*p<0.05 559 
 560 
Figure 3: Chronic activation of ER stress does not worsen foz/foz phenotype 561 
(A) Quantification of eIF2α and JNK phosphorylation and IRE1α protein levels assessed by western 562 
blot, (B) expression of adaptive and pathologic ER stress response target genes assessed by RT-qPCR, 563 
(C) Xbp1 splicing, (D) expression of lipogenic genes measured by RT-qPCR, (E) IP glucose tolerance 564 
test (area under the curves p=0.15), (F) Haematoxylin and eosin staining of liver sections (10X 565 
magnification), (G) expression of F4/80 and CD68 mRNA assessed by RT-qPCR and (H) quantification 566 
of apoptotic cells stained using M30 antibody for cleaved cytokeratin 18 in 5 weeks HFD-fed foz/foz 567 
mice treated for 4 weeks with tunicamycin (TUN or hatched bars) or not (CTL or open bars). *p<0.05  568 
 569 
Figure 4: TUDCA decreases UPR and steatosis but fails to reduce JNK and Chop and to improve 570 
glucose intolerance, hepatic insulin signalling, inflammation and apoptosis in HFD-fed foz/foz mice 571 
RNA and total proteins were extracted from whole livers of 6 week HFD-fed foz/foz mice that 572 
received TUDCA IP injections for the last 2 weeks (TUDCA or dotted bars) and pair-fed controls (pair-573 
fed or open bars). (A) Quantification of eIF2α and JNK phosphorylation and IRE1α protein levels 574 
assessed by western blot. (B) Expression of adaptive and pathologic ER stress response target genes 575 
assessed by RT-qPCR. (C) Expression of lipogenic genes measured by RT-qPCR. (D) IP glucose 576 
tolerance test (area under the curves p=0.92). (E) Haematoxylin and eosin staining (left panels) and 577 
F4/80 immunohistochemistry (right panels) of the liver sections (10X magnification). (F) Expression of 578 
F4/80 and CD68 assessed by RT-qPCR. (G) Quantification of apoptotic cells stained using M30 579 
antibody for cleaved cytokeratin 18. *p<0.05 580 
 581 
  582 
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Tables 583 
 584 
Table 1: Metabolic parameters in foz/foz mice fed normal diet (ND) or high-fat diet (HFD) for 6 weeks 585 
after weaning 586 
 587 
 588 
  589 
 
ND HFD p value 
n 5 9  
Body weight (g) 22.5 ± 1.9 48.7 ± 2.6 2.10
-10
 
Liver weight (g) 1.31 ± 0.19 2.64 ± 0.42 3.10
-6
 
Liver/body (%) 5.81 ± 0.51 5.40 ± 0.65 0.22 
Hepatic lipid content (mg/100mg tissue) 7.36 ± 3.68 43.08 ± 13.82 9.10
-5
 
Epididymal adipose tissue weight (g) 0.32 ± 0.13 2.71 ± 0.31 2.10
-10
 
Epididymal adipose tissue/body (%) 1.41 ± 0.55 5.60 ± 0.81 2.10
-7
 
Fasting glycaemia (mg/dL) 148 ± 21 229 ± 9 0.03 
Insulin C-peptide (pM) 1652 ± 1079 2552 ± 1529 0.15 
Alanine aminotransferase (IU/L) 50.3 ± 6.9 108.0 ± 55.2  0.02 
Total caloric intake (kcal/day) 8.33 ± 0.58 17.85 ± 2.98 0.0002 
Caloric intake from fat (kcal/day) 1.33 ± 0.09 10.71 ± 1.79 0.00002 
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 590 
Table 2: Metabolic parameters in high-fat diet-fed foz/foz mice treated or not with tunicamycin in a 591 
chronic setting 592 
 593 
 594 
  595 
 
Control Tunicamycin p value 
n 5 5  
Body weight (g) 38.0 ± 3.9 36.0 ± 5.22 0.30 
Body weight gain (g) + 17.7 ± 3.0 + 19.2 ± 2.4 0.41 
Liver weight (g) 2.24 ± 0.52 2.33 ± 0.50 0.79 
Hepatic lipid content (mg/100mg tissue) 38.52 ± 10.73 28.88 ± 10.01 0.18 
Epididymal adipose tissue weight (g) 2.01 ± 0.43 2.40 ± 0.59 0.28 
Fasting glycaemia (mg/dL) 224 ± 49 239 ± 73 0.71 
Insulin C-peptide (pM) 1345 ± 178 1464 ± 554 0.67 
Alanine aminotransferase (IU/L) 106.0 ± 28.3 120.3 ± 40.4 0.67 
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 596 
Table 3: Metabolic parameters in high-fat diet-fed foz/foz mice treated or not with TUDCA 597 
 598 
 599 
 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
  608 
 
pairfed control  TUDCA p value 
n 7 6  
Body weight (g) 36.9 ± 4.6 36.0 ± 5.22 0.77 
Liver weight (g) 1.68 ± 0.26 1.43 ± 0.09 0.046 
Liver/body (%) 4.54 ± 0.27 4.02 ± 0.42 0.031 
Hepatic lipid content (mg/100mg tissue) 20.6 ± 4.5 13.2 ± 3.3 0.006 
Epididymal adipose tissue weight (g) 2.13 ± 0.50 1.82 ± 0.53 0.30 
Fasting glycaemia (mg/dL) 201 ± 41 171 ± 35 0.21 
Insulin C-peptide (pM) 634 ± 278 558 ± 101 0.55 
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Summary statement 609 
Unlike in mice developing simple steatosis, endoplasmic reticulum stress does not contribute to the 610 
pathogenesis of insulin resistance and steatohepatitis in high-fat diet-fed foz/foz mice, which develop 611 
the progressive liver disease in the metabolic context seen in human non-alcoholic steatohepatitis. 612 
 613 
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Material and methods  
 
Animals and treatment 
Six week-old male ob/ob mice and their lean (ob/+) littermates were purchased from Janvier 
(France), fed chow and maintained in the animal facility of Université catholique de Louvain 
(Brussels, Belgium) for 3 weeks. Treatment was initiated after 1 week acclimation. 
At the time of sacrifice, anesthetized (ketamine/xylazine) mice received 5 U insulin (Actrapid, Novo 
Nordisk, Bagsvaerd, Denmark) or an equal volume of PBS into the portal vein to analyse the 
intrahepatic response to insulin. The liver was removed 1 min after the injection, and epididymal 
adipose tissue were dissected and weighed. Portions of tissue were immersed in formalin 4% for 
histology; the remaining tissue was snap frozen in liquid nitrogen and kept at -80°C until analyses. 
 
Histology and immunohistochemistry 
Formalin-fixed, paraffin-embedded sections were used for histological evaluation with haematoxylin 
and eosin (H&E) staining. Steatosis was estimated by counting the number of fatty hepatocytes in 
relation to the total number of hepatocytes and expressed as percentage of steatosis. Quantification 
has been performed on minimum 8  fields (objective 10X, magnification 100X). 
Tissue sections underwent antigen retrieval (sodium citrate) and antibody labelling. F4/80 was 
detected using a primary rat anti-mouse F4/80 monoclonal antibody (1/200, Serotec, Oxford, UK), a 
rabbit anti-rat immunoglobulin (1/200, Dako, Glostrup, Denmark) and then a goat anti-rabbit 
streptavidin horseradish peroxidase conjugated antibody (En Vision, Dako). Cleaved cytokeratine 18 
(M30 epitope) was detected using a primary mouse antibody (1/100, Roche) and the MOM kit 
according to the manufacturer recommendations (Dako). The peroxidase activity was revealed with 
diaminobenzidine and slides were counterstained with haematoxylin. Quantification was performed 
in a minimum of 5 random 20X-power fields per section. 
 
Glucose homeostasis assessment  
Blood was retrieved from the tail vein on 4-hours fasted mice and used to measure glucose (Accu-
chek Aviva; Roche) and C-peptide plasma concentration using an enzyme immunoassay (ALPCO, 
USA).  
To evaluate glucose tolerance, glucose (1 g/kg body weight) was injected IP after a fasting period of 4 
hours, and glucose levels were monitored in tail blood at 0, 15, 30, 60, 90, 120 and 180 min after the 
injection. Glucose tolerance test was performed 2 days prior to sacrifice, or after 12 days of TUDCA, 
PBA or vehicle treatment.  
 
Lipid and protein analyses  
Total liver lipids were extracted with methanol and chloroform and quantified using the vanillin 
phosphoric acid reaction [1]. To analyse the ER stress response, proteins from liver homogenates 
(100 µg) were assayed by western blotting using the antibodies and conditions listed in 
Supplementary Table 1. Immunoreactivity was detected with a horseradish peroxidase-conjugated 
secondary antibody and enhanced chemiluminescence reagents (Western Lightning 
Chemiluminescence Reagent Plus; Perkin Elmer). One membrane was sequentially probed with the 
antibodies against the total protein, the phospho-protein, and GAPDH or beta-actin to control for 
protein loading. The quantification of immunoreactive proteins was obtained by densitometry using 
the Gel DocTM XR System 170–8,170 device and software (Bio-Rad). The levels of immunoreactivity 
relative to the invariant control are reported as arbitrary densitometry units. Phosphorylation was 
estimated by calculating the ratio of phospho-protein divided by the total form of the protein. 
 
RNA extraction, reverse transcription and real time quantitative PCR (RT-qPCR)  
Total RNA was extracted from frozen liver using TRIpure Isolation Reagent (Roche Diagnostics 
Belgium, Vilvoorde, Belgium). cDNA was synthesized from 1 µg RNA using random primers and M-
MLV RT (Invitrogen, Merelbeke, Belgium). Real-time PCR analysis was performed as described 
previously [1]. Primer pairs for transcripts of interest were designed using the Primer Express design 
software (Applied Biosystems, Belgium) and are listed in Supplementary Table 2. RPL19 mRNA was 
chosen as an invariant standard. All experimental tissues and standard curve samples were run in 
duplicate in a 96-well reaction plate (MicroAmp Optical; Applied Biosystems). Results are expressed 
as fold expression relative to expression in the control group using the ΔΔCt method [1]. 
 
 
Supplementary Figure legends 
 
Supplementary Figure 1: Comparison of ER stress response between foz/foz and ob/ob models 
RNA and total proteins were extracted from whole livers of 9 week-old ob/ob mice (pale grey bars), 
their lean littermates (white bars) and foz/foz mice fed normal diet (foz+ND or dark grey bars) or 
high-fat diet (foz+HFD or hatched bars) for 6 weeks. (A) Quantification of eIF2α phosphorylation and 
IRE1α protein expression assessed by western blot. (B) Expression of UPR target genes assessed by 
RT-qPCR. (C) Expression of lipogenic genes measured by RT-qPCR. * p<0.05 ob/ob vs. lean. Ϯ p<0.05 
foz+HFD vs. ob/ob. ¥ p<0.05 foz+HFD vs. foz+ND 
 
Supplementary Figure 2: ER-stress response in male (A-D) and female (E-G) foz/foz mice at 
different time points of HFD feeding 
RNA and total proteins were extracted from livers of male foz/foz mice after 3 days and 16 weeks of 
HFD to evaluate (A) eIF2α phosphorylation by western blot, (B) Xbp1 splicing, (C-D) expression of UPR 
target genes by RT-qPCR. (E) Grp78 protein, (F) Chop mRNA and (G) nuclear protein expression at 12 
and 24 weeks in female WT and foz/foz mice fed chow or HFD. * p <0.05, vs diet-matched control. 
#p<0.05, vs genotype-matched control. 
 
Supplementary Figure 3: ER-stress response induced by tunicamycin in foz/foz mice 
ND-fed foz/foz mice were treated with tunicamycin 1.0 mg/kg BW, IP (Tun, hatched bars) or vehicle 
(ND, plain bars) and the liver analysed 6 hours later. (A) eIF2α phosphorylation and IRE1α protein 
levels assessed by western blot (left panel) and quantification (right panel); (B) XBP1 splicing; (C) 
expression of target genes of adaptive UPR by RT-qPCR; (D) phosphorylation of JNK and nuclear Chop 
protein level assessed by western blot; (E) expression of pro-apoptotic UPR target genes measured 
by RT-qPCR.  *p<0.05 
 
Supplementary Figure 4: Hepatic insulin signaling in foz/foz mice 
Insulin sensitivity was evaluated by phosphorylation of signalling intermediates (p-IR on 
Tyr1162/1163, p-AKT on Ser473 and on Thr308) upon insulin stimulus as determined by western blot 
in (A) foz/foz mice fed ND or HFD for 6 weeks, (B) 5 weeks HFD-fed foz/foz mice treated for 4 weeks 
with tunicamycin (TUN) or not (CTL) and (C) 6 week HFD-fed foz/foz mice that received TUDCA IP 
injections for the last 2 weeks (+TUDCA) and pair-fed HFD controls (-TUDCA). 
 
Supplementary Figure 5: Side by side comparison of TUDCA effect in ob/ob and foz/foz models 
4 week HFD-fed foz/foz mice and chow-fed ob/ob mice received simultaneously TUDCA IP injections 
during 2 weeks (TUDCA or dotted bars). Pair-fed controls (pair-fed or open bars) received PBS IP 
injections. RNA and total proteins were extracted from whole livers. (A) Quantification of eIF2α and 
JNK phosphorylation and IRE1α protein expression assessed by western blot. (B) Expression of UPR 
target genes assessed by RT-qPCR. (C) Expression of lipogenic genes measured by RT-qPCR. (D) IP 
glucose tolerance test (area under the curves p=0.92 for foz/foz mice TUDCA vs. pair-fed; p=0.05 for 
ob/ob mice TUDCA vs. pair-fed). (E) Haematoxylin and eosin staining of the liver sections (10X 
magnification). *p<0.05 TUDCA vs. respective pair-fed controls 
 
 
  
Supplementary Table 1: List of the antibodies used in western blotting 
 
  
Protein Epitope # Antibody Isotype Source 
eIF2α 
 
9722 rabbit Cell Signalling 
p-eIF2α Ser 51 3398 rabbit Cell Signalling 
IRE1α His963 3294 rabbit Cell Signalling 
JNK/SAPK 
 
sc-571 rabbit Santa Cruz 
p-JNK/SAPK Thr183/Tyr185 4668 rabbit Cell Signalling 
GAPDH 
 
2118 rabbit Cell Signalling 
β-actin 
 
A5441 mouse Sigma 
Akt 
 
610861 mouse BD Transduction Laboratories 
p-Akt Ser473 4060 rabbit Cell Signalling 
p-Akt Thr308 2965 rabbit Cell Signalling 
IR 
 
sc-711 rabbit Santa Cruz 
p-IR Tyr1162/1163 sc-25103 rabbit Santa Cruz 
Supplementary Table 2: List of the primers used in PCR 
Gene RefSeq Forward primer Reverse primer 
Acc-1 NM_133360 TGTCCGCACTGACTGTAACCA TGCTCCGCACAGATTCTTCA 
Atf4 NM_009716.2 CTCAGACAGTGAACCCAATTGG GGCAACCTGGTCGACTTTTATT 
Bim NM_207680  AGGAGGGTGTTTGCAAATGATT ACCAGACGGAAGATAAAGCGTAA 
CD68 NM_009853 TGCGGCTCCCTGTGTGT TCTTCCTCTGTTCCTTGGGCTAT 
Chop NM_007837.3 AGGAGCCAGGGCCAACA TCTGGAGAGCGAGGGCTTT 
Edem NM_138677  GGATCCCCTATCCTCGGGT GTTGCTCCGCAAGTTCCAG 
Fasn NM_007988 GATCCTGGAACGAGAACACGAT AGAGACGTGTCACTCCTGGACTT 
F4/80 NM_010130 GATGAATTCCCGTGTTGTTGGT ACATCAGTGTTCCAGGAGACACA 
Gadd34 NM_008654.2 TGGTCCAGCTGAGAATGAAGAG GGAAGCAGCAGAAGCTTGGT 
Grp78 NM_022310.2 AGCCATCCCGTGGCATAA GGACAGCGGCACCATAGG 
Hsp90 NM_011631  TGTTGTGGATTCCGATGATCTC GCAATTTATGTTGCTGAAGAGTCTCA 
Nqo1 NM_008706 CAATCAGCGTTCGGTATTACGA GCCAGTACAATCAGGGCTCTTC 
Pemt NM_008819 GCGGCTGTGATCACCATTG TCCCATCTCGCTACCACATTC 
Rpl19 NM_009078 GAAGGTCAAAGGGAATGTGTTCA CCTTGTCTGCCTTCAGCTTGT 
Scd-1 NM_009127 CCAGAATGACGTGTACGAATGG GCGTGTGTTTCTGAGAACTTGTG 
Srebp1 NM_011480 CTGGCACTAAGTGCCCTCAAC GCCACATAGATCTCTGCCAGTGT 
Trib3 NM_175093  TGTCTTGCGCGACCTCAAG CCAGCTTCGTCCTCTCACAGT  
Xbp1* NM_013842.2 ACACGCTTGGGAATGGACAC CCATGGGAAGATGTTCTGGG 
*PCR product loaded on a 3% agarose gel (spliced=147bp; unspliced=173bp) 
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